Sign in Subscribe
Communicable diseases

Vector-Priming Enhances Immunogenicity of Live Recombinant Salmonella Vaccine

Strategic Insights

— 1 min read

The study aimed to assess the impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. The research involved 13 volunteers who were preimmunized with Salmonella Typhi Ty21a and then received doses of a recombinant vaccine strain or placebo. The results showed that prior immunization with the carrier strain increased the immunogenicity of the vaccine, with 56% of volunteers showing cellular immune responses to H. pylori urease.

Key Takeaways:

  • The live recombinant Salmonella vaccine expressing H. pylori urease A and B showed improved immunogenicity in volunteers who were preimmunized with the carrier strain.
  • The study involved 13 human volunteers, with 9 receiving the recombinant vaccine strain and 4 receiving the placebo strain.
  • Four volunteers were preimmunized and boosted with the vaccine strain, while nine were preimmunized with the carrier strain and then received the recombinant vaccine.
  • The results showed that vector-priming, where a carrier strain is used to prime the immune system before receiving the recombinant vaccine, enhances the immunogenicity of the vaccine.
  • The study's findings support the results of a previous study, which also found a 56% cellular immune response to urease in non-preimmunized volunteers.
  • The researchers observed no serious adverse effects in any of the volunteers.

Statistics:

  • 56% of volunteers who were preimmunized with the carrier strain showed cellular immune responses to H. pylori urease.
  • 9 volunteers received the recombinant vaccine strain, while 4 received the placebo strain.
  • The study occurred in 2004.
  • 4 volunteers were preimmunized and boosted with the vaccine strain.
  • 5 volunteers showed cellular immune responses to H. pylori urease after receiving the recombinant vaccine.

Sources:

  • Metzger, W. G., et al. (2004) "Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers". Vaccine, 22(17-18), 2273-2277.
  • Max-Planck-Institut fur Infektionsbiologie, Abteilung Molekulare Biologie.
  • Elsevier Science Ltd.
  • Health & Medicine Week editors.

Read more